TGFB1 and neoplasm: Furthermore, the combination of multiple immunotherapies, such as TGF-β inhibitors, oncolytic viruses, tumor vaccines, and adoptive cell therapy, has shown a good safety and tolerability profile, but clinical outcomes must be evaluated further [29,30,36].